Linc invests in product oriented companies in the Nordic Life Science industry. We mainly invest in and develop small and medium-sized product oriented life science companies in Medical Technology and Pharmaceuticals.
The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an early phase compared with investments in medical technology.
Linc is an active and long-term owner with a broad industrial network to support the portfolio companies. We work together with management, founders and the board to realize the inherent potential that exists in the company, have ambitious plans for further development and expansion and actively participate in the nomination committee’s work.
1991
Served areaNordics
HeadquartersStrandvägen 7A, 11451 Stockholm – Sweden
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Assets | N/A | 2,638,391,000.00 | 3,763,411,000.00 | 2,912,443,000.00 |
Noncurrent Assets | N/A | 2,611,225,000.00 | 2,933,193,000.00 | 2,286,056,000.00 |
Noncurrent Receivables Due From Related Parties | N/A | 7,651,000.00 | 17,801,000.00 | 17,801,000.00 |
Current Assets | N/A | 27,167,000.00 | 830,218,000.00 | 626,387,000.00 |
Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | N/A | 384,000.00 | 500,000.00 |
Other Current Financial Assets | N/A | 5,003,000.00 | 1,141,000.00 | 25,340,000.00 |
Cash and cash equivalents | 36,534,000.00 | 21,908,000.00 | 828,693,000.00 | 600,547,000.00 |
Equity And Liabilities | N/A | 2,638,391,000.00 | 3,763,411,000.00 | 2,912,443,000.00 |
Equity | 1,661,045,000.00 | 2,494,225,000.00 | 3,632,932,000.00 | 2,909,596,000.00 |
Issued Capital | N/A | 100,000.00 | 5,791,000.00 | 5,791,000.00 |
Retained Earnings | N/A | 2,494,125,000.00 | 2,460,196,000.00 | 1,736,860,000.00 |
Share Premium | N/A | 0.00 | 1,166,945,000.00 | 1,166,945,000.00 |
Noncurrent Liabilities | N/A | 142,005,000.00 | 125,821,000.00 | 0.00 |
Deferred Tax Liabilities | N/A | 142,005,000.00 | 125,821,000.00 | 0.00 |
Current Liabilities | N/A | 2,161,000.00 | 4,658,000.00 | 2,847,000.00 |
Trade And Other Current Payables To Trade Suppliers | N/A | 581,000.00 | 410,000.00 | 147,000.00 |
Current Tax Liabilities Current | N/A | 0.00 | 43,000.00 | 55,000.00 |
Current Financial Liabilities At Fair Value Through Profit Or Loss | N/A | 422,000.00 | 47,000.00 | 0.00 |
Other Current Liabilities | N/A | 243,000.00 | 258,000.00 | 252,000.00 |
Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
---|---|---|---|
Revenue From Dividends | 1,311,000.00 | 4,138,000.00 | 2,371,000.00 |
Other Income | 0.00 | 6,130,000.00 | 4,860,000.00 |
Employee Benefits Expense | 2,503,000.00 | 9,412,000.00 | 7,747,000.00 |
Other Gains Losses | 974,416,000.00 | -16,986,000.00 | -887,368,000.00 |
Profit Loss From Operating Activities | 970,052,000.00 | -37,143,000.00 | -898,426,000.00 |
Finance Income | 244,000.00 | 216,000.00 | 2,515,000.00 |
Finance Costs | 8,000.00 | 1,174,000.00 | 0.00 |
Profit Loss Before Tax | 970,288,000.00 | -38,101,000.00 | -895,911,000.00 |
Income Tax Expense Continuing Operations | 137,108,000.00 | -8,072,000.00 | -172,576,000.00 |
Profit (loss) | 833,180,000.00 | -30,029,000.00 | -723,335,000.00 |
Profit Loss Attributable To Owners Of Parent | 833,180,000.00 | -30,029,000.00 | -723,335,000.00 |
Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Profit (loss) | N/A | 833,180,000.00 | -30,029,000.00 | -723,335,000.00 |
Adjustments For Fair Value Gains Losses | N/A | -974,416,000.00 | 23,116,000.00 | 892,229,000.00 |
Other Adjustments For Noncash Items | N/A | 514,000.00 | 2,894,000.00 | -1,432,000.00 |
Interest Paid Classified As Operating Activities | N/A | 7,000.00 | 1,174,000.00 | 0.00 |
Interest Received Classified As Operating Activities | N/A | 0.00 | 344,000.00 | 2,356,000.00 |
Income Taxes Paid Refund Classified As Operating Activities | N/A | -59,000.00 | -484,000.00 | -5,000.00 |
Cash Flows From Used In Operating Activities | N/A | -14,626,000.00 | -353,839,000.00 | -228,147,000.00 |
Cash Flows From Used In Investing Activities | N/A | 0.00 | 0.00 | 0.00 |
Proceeds From Issuing Shares | N/A | 0.00 | 1,200,000,000.00 | 0.00 |
Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 182,033,000.00 | 0.00 |
Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 182,033,000.00 | 0.00 |
Cash Flows From Used In Financing Activities | N/A | 0.00 | 1,160,625,000.00 | 0.00 |
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -14,626,000.00 | 806,786,000.00 | -228,147,000.00 |
Cash and cash equivalents | 36,534,000.00 | 21,908,000.00 | 828,693,000.00 | 600,547,000.00 |
Please note that some sums might not add up.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
13.02.23 | Bengt Julander | Other | Other | SEK 14,100,000.00 |
31.05.21 | Anders Erik Hansen | Other | Buy | SEK 1,608,000.00 |
28.05.21 | Karl Tobieson | Other | Other | SEK 180,900.00 |
SE0015949433
LEI549300UFJU04UGB49K16
SectorAsset Management & Custody Banks
Listed Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.